Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 9/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.35 |
| ▸ | KIF11 | P52732 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.33 |
| ▸ | SCD | O00767 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5107354 | 0.85 | KIF11 (0.35) | KIF11KDM4EALDH1A1BRD4CYP2C9 | |
| SCHEMBL5108306 | 0.83 | KIF11 (0.43) | KIF11 | |
| SCHEMBL4513091 | 0.81 | KIF11 (0.48) | AAK1KIF11KDM4EALDH1A1HPGD | |
| SCHEMBL5112019 | 0.77 | KIF11 (0.43) | KIF11KDM4E | |
| SCHEMBL4096829 | 0.75 | KIF11 (0.44) | KIF11KDM4EALDH1A1HPGDBRD4 | |
| SCHEMBL5120055 | 0.74 | KIF11 (0.39) | KIF11KDM4EALDH1A1HPGDBRD4 | |
| SCHEMBL14544725 | 0.73 | PDE4A (0.45) | KIF11ALDH1A1 | |
| SCHEMBL14393453 | 0.73 | PDE4A (0.45) | KIF11ALDH1A1 | |
| SCHEMBL13956803 | 0.71 | P2RX7 (0.42) | P2RX7KIF11BRD4 | |
| SCHEMBL5523051 | 0.70 | KIF11 (0.49) | KIF11KDM4EBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332498-B2 | Modulation of KSP kinesin activity with heterocyclic-fused pyrimidinone derivatives | CYTOKINETICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20060111374-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2006-05-25 | — | — | US | disclosed |
| US-7038048-B2 | 3H-pyridopyrimidin-4-one compounds, compositions, and methods of their use | CYTOKINETICS, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| US-20040116438-A1 | Compounds, compositions, and methods | CYTOKINETICS, INCORPORATED | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111374-A1 | Compounds, compositions, and methods | ALPP, MKI67, PCNA | AAK1 3056/4885P2RX7 4801/4885P2RX3 4786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.